[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire Saint Pierre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":224},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,44,65,97,131,160,183,202],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100630360","a-pilot-project-for-plwh-aged-65-75-preventing-the-development-of-frailty-100630360",false,"NCT07486661","A Pilot Project for PLWH Aged 65-75: Preventing the Development of Frailty","Frailty","Inclusion Criteria:\n\n* living with HIV\n* between 65-74 years\n\nExclusion Criteria:\n\n* none","ALL","65 Years","74 Years",{"count":20,"type":21},100,"ESTIMATED","1 Year","OBSERVATIONAL","In ageing populations, the main risk is the development of a syndrome of frailty, characterized by the addition of polymorbidity, polymedication, psychosocial difficulties, cognitive disorders, ... This functional decline is linked to a reduction in the person's functional reserves, and will lead to an increase in health problems, hospitalizations and, ultimately, mortality. People living with HIV (PLWH) over 50 develop the same kind of comorbidities as HIV-uninfected people over 75 years-old.\n\nIn Belgium, the care of PLWH\\\u003C 75 years with frailty syndrome is not reimbursed by healthcare insurance, and geriatric assessment and management is therefore not possible in this age group, despite the very real need.\n\nGoals of this project are:\n\n1. Determine the proportion and characterize the population of PLWH aged 65 and over who screen positive using the Fried scale\n2. Validate the application of the Fried scale in a population of PLWH\n3. Offer a care pathway model to prevent the onset of frailty in people screened as at-risk and who do not benefit from routine screening or care pathway reimbursement.\n\nProjets proposal:\n\n* Systematic screening of all PLWH aged 65-74 at the MIA Center, by the nurse prior to physician consultation, using the Fried scale.\n* Send all PLWH aged 65-74 who screen positive to Geriatric One Day for an ergo-geriatric consultation to confirm the risk of frailty and set up a preventive care pathway\n* After treatment, perform a patient satisfaction questionnaire + a new Fried scale at one year",[26,27],"Age Group: 65-74","HIV",[27,29,30],"frailty","ageing","RECRUITING","2026-03-18",{"date":34,"type":35},"2026-03-20","ACTUAL",{"date":37,"type":35},"2025-08-28",{"date":39,"type":21},"2028-07",{"name":41,"class":42},"Centre Hospitalier Universitaire Saint Pierre","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":54,"studyType":23,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":43},"100625625","upper-gastrointestinal-endoscopy-in-hiv-infected-individuals-100625625","NCT07425067","Upper Gastrointestinal Endoscopy in HIV-infected Individuals","Inclusion criteria: adults aged 18 years or older; first upper gastrointestinal endoscopy; written informed consent.\n\nExclusion criteria: inability to provide informed consent or refusal.","18 Years","99 Years",{"count":53,"type":21},2500,"1 Day","The aim of this registry is to collect prospectively demographic characteristics and upper gastrointestinal endoscopy diagnoses over a long-term period, in people living with HIV, undergoing upper gastrointestinal endoscopy",[27],"2026-02-13",{"date":59,"type":35},"2026-02-20",{"date":61,"type":35},"2004-01-01",{"date":63,"type":21},"2027-01-01",{"name":41,"class":42},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100574592","optimizing-patient-selection-for-surgery-using-pathologic-analysis-following-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-100574592","NCT06761287","Optimizing Patient Selection for Surgery Using Pathologic Analysis Following Neoadjuvant Therapy in Locally Advanced Rectal Cancer","Role of Local Endoscopic Excision After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Prospective Study","OPAL","Inclusion Criteria:\n\n* Age \\> 18 years old\n* Signed informed consent\n* Patients diagnosed with locally advanced rectal cancer showing complete or near-complete clinical response after neoadjuvant therapy without evidence of invasive disease (\\>T2) or locoregional invasion on magnetic resonance imaging and without any signs of metastatic disease on a computerized tomography scan.\n* Patients diagnosed with locally advanced rectal cancer showing incomplete response with presence of superficial residual lesions, without invasive features on endoscopic evaluation, without evidence of invasive disease (\\>T2) or locoregional invasion on magnetic resonance imaging and without any signs of metastatic disease on a computerized tomography scan.\n* Without previous medical history of rectal cancer or rectal surgery\n\nExclusion Criteria:\n\n* Previous medical history of rectal cancer\n* Previous rectal surgery",{"count":74,"type":21},20,"INTERVENTIONAL",[77],"NA","This interventional, non-randomized, prospective trial aims to evaluate the role of endoscopic resection following neoadjuvant treatment in patients with locally advanced rectal cancer.\n\nPhase I focuses on assessing the feasibility, safety and efficacy of endoscopic resection of residual scar or superficial residual neoplastic tissue following neoadjuvant treatment.\n\nPhase II explores the potential of this approach to guide patient selection for total mesorectal excision and to serve as a definitive treatment option for those with limited residual disease.",[80],"Locally Advanced Rectal Cancer (LARC)",[82,83,84,85,86,87,88],"locally advanced rectal cancer","neoadjuvant","endoscopic resection","endoscopic submucosal dissection","endoscopic intermuscular dissection","feasibility","safety","2025-05-25",{"date":91,"type":35},"2025-05-30",{"date":93,"type":35},"2025-03-28",{"date":95,"type":21},"2030-12",{"name":41,"class":42},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":104,"minAge":50,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":75,"phases":108,"briefSummary":109,"conditions":110,"keywords":118,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":43},"100579772","treatment-of-vulvo-vaginal-atrophy-vva-using-vaginal-dilator-in-addition-to-usual-treatment-100579772","NCT06828640","Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment","Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment : a Randomized Control Trial","Inclusion Criteria:\n\n* Peri- or postmenopausal women suffering from vulvovaginal atrophy (VVA)\n* Breast cancer survivors with VVA symptoms\n* Understand the study, be willing to participate, and sign an informed consent form.\n* The use of estrogen\u002Fprogestogen-based products (vaginal, oral, pellets, transdermal, etc.) is permitted but must be documented (this will be considered during randomization).\n\nExclusion Criteria:\n\n* Undiagnosed abnormal genital bleeding.\n* Administration of any investigational drug within 30 days prior to the screening visit.\n* Presence of a serious medical condition, neurological disorder, or significant comorbidities.\n* Other gynecological malignancies.\n* Recent vaginal surgery.\n* Clinically significant prolapse (POP-Q ≤ 2).\n* Current urinary tract or vaginal infection, or recent sexually transmitted infection.\n* Individuals with disabilities unable to communicate.\n* Women eligible for the study but unwilling to participate.","FEMALE","85 Years",{"count":107,"type":21},160,[77],"This is a randomized, controlled trial aiming to evaluate the effectiveness of adding vaginal dilators to the treatment of vulvovaginal atrophy.\n\nStudy Population:\n\nPeri- and postmenopausal women with VVA, including breast cancer survivors.\n\nDesign: Monocentric pilot RCT evaluating SoC (MHT, lubricants, moisturizers) (control group) to SoC + vaginal dilators (test group).\n\nVaginal Dilator : A silicone medical device will be used for gradual stretching progression. The kit includes dilators of progressively larger sizes.\n\nProcedures: Assessments at baseline, at 4 \\& 12 weeks\n\nMeasures : Vulvo Vaginal Atrophy severity , dyspareunia, Vaginal Health Index Score, Female Sexual Fonction Index, and Visual Analogue Scale (for vaginal dryness, vaginal and\u002For vulvar irritation\u002Fitching, and pain during sexual intercourse).\n\nStatistical Analysis:\n\nDifferences at baseline, 4 weeks, and 12 weeks will be tested using:\n\nTwo-sample t-test Mann-Whitney test\n\nStatistical Power:\n\nAssuming a 20% improvement in Group 1 and 40% in Group 2, with:\n\np \\\u003C 0.05 (type I error) 80% power (type II error), 160 patients needed across both groups.\n\nSoC = Standard of care RCT = Randimized control trial MHT = Menopausal hormonal therapy",[111,112,113,114,115,116,117],"Vulvo Vaginal Atrophy","Genitourinary Syndrome of Menopause (GSM)","Vaginal Atrophy in Breast Cancer Patients","Vaginal Atrophy Patients With GSM","Treatment","Sexual Disfunction","Dyspareunia (Female)",[119,120,121,122],"Vulvo vaginal atrophy","vaginal dilators","Genitourinary syndrome of menopause","treatment","2025-02-11",{"date":125,"type":35},"2025-02-14",{"date":127,"type":35},"2024-10-16",{"date":129,"type":21},"2025-10",{"name":41,"class":42},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":138,"enrollmentInfo":139,"targetDuration":141,"studyType":23,"phases":4,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":43},"100579312","dreams-or-implicite-memorization-under-ofa-100579312","NCT06822660","Dreams or Implicite Memorization Under OFA","Dreams","Inclusion Criteria:\n\n* laparoscopic robotic surgery\n* ASA score 1 to 3\n\nExclusion Criteria:\n\n* neurological and psychiatric diseases\n* reflect memory disorders\n* head trauma\n* hearing disorders\n* past or current use of medications affecting the central nervous system.","75 Years",{"count":140,"type":21},40,"1 Week","The Dreams study is an observational study aimed at evaluating the incidence of connected awareness after intubation, intraoperative explicit and implicit memorization, and postoperative well-being in patients receiving general anesthesia without opioids.\n\nOutcomes\n\nThe primary objective is the evaluation of the incidence of connected consciousness after induction of general anesthesia without opioids and intubation. The secondary objectives are:\n\n* Implicit and explicit memorization after intubation and during the procedure\n* Post-operative well-being Pain in the recovery room and in the room, assessed by VAS;\n* Total consumption of analgesics (paracetamol, diclofenac, tramadol): data collected during discharge\n* Level of satisfaction, assessed using the EVAN scale\n* Duration of hospitalization\n* Estimated first mobilization",[144],"Implicite Memorization",[146,147,148,149,150,151],"implicite memorization","opioid free anesthesia","observationnal","monocentric","isolated forearm technique","explicite memorization","2025-02-07",{"date":154,"type":35},"2025-02-12",{"date":156,"type":35},"2024-11-25",{"date":158,"type":21},"2025-06-15",{"name":41,"class":42},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":43},"100578692","prevalence-of-non-alcoholic-fatty-liver-disease-in-inflammatory-bowel-disease-patients-100578692","NCT06814600","Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients","Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients: A Prospective Monocentric Study","PONI","Inclusion Criteria:\n\n* Diagnosis of IBD based on clinical, endoscopic, and histological gounds according to the latest ECCO guidelines\n* Willingness to provide informed consent for study participation\n\nExclusion Criteria:\n\n* Presence of established liver disease (including autoimmune hepatitis, primary biliary cholangitis, primary biliary cirrhosis, hemochromatosis, Wilson's disease, positive serology for viral hepatitis B or C)\n* History of hepatocellular carcinoma or liver transplantation\n* History of excessive alcohol consumption defined as \\>3 units per day for women and \\> 5 units per day for men\n* Pregnancy at the time of recruitment\n* Failure to perform an elastography mesure or missing elastography data",{"count":169,"type":21},150,"Non-alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disease characterized by the presence of more than 5% of steatosis in hepatocytes of individuals who consume little or no alcohol. It ranges from simple steatosis without evidence of inflammation, to the association of steatosis and inflammation with cellular necrosis, the so-called non-alcoholic steatohepatitis (NASH). NAFLD has become increasingly common in developed countries affecting up to 38% of the population. It is mostly but not exclusively associated with metabolic syndrome including obesity, insulin resistance, and hypertension. There is growing evidence of a close interaction between the gut and the liver \"Gut-liver axis\", particularly in the pathogenesis of NAFLD. The pathophysiological mechanism behind this association is not well understood but involves small intestinal bacterial overgrowth (SIBO), intestinal wall inflammation and increased permeability, all leading to systemic translocation of microbial metabolites including endotoxins and pro-inflammatory markers called Pathogen Associated Molecular Pattern (PAMPs). Thus, the gut-liver interaction, mediated by cytokines and inflammatory proteins seem to be the cornerstone of this complex liver disease.\n\nRecent studies underlined the increased prevalence of NAFLD in the Inflammatory Bowel Disease (IBD) population, accounting for almost 32% of hepatic extra-intestinal manifestations of the disease. Several hypotheses have been proposed to explain the pathophysiology behind this association, encompassing chronic intestinal wall inflammation, increased intestinal permeability and altered gut microbiota or dysbiosis. To our knowledge, no studies have been conducted so far to investigate the correlation between intestinal disease activity (IBD flare versus remission state) and NAFLD incidence and behavior (progression versus regression of steato-fibrosis). We therefore aim to conduct a prospective paired study, on IBD patients followed at Saint-Pierre University Hospital, aiming to explore this correlation.\n\nIn this paired study design, patients will be their own controls over the course of their disease: An evaluation of NAFLD will be done for all patients during both phases of their inflammatory bowel disease: In the active phase and in remission phase. Our primary outcome is to assess NAFLD prevalence in the IBD population followed at our institution. Secondary outcomes will be to explore NAFLD prevalence and behavior (progression versus regression of steato-fibrosis) according to IBD activity, IBD type, IBD duration and types of IBD treatments.",[172,173,174,175],"NAFLD","Inflammatory Bowel Diseases","Steatosis","Fibrosis, Liver","2025-02-05",{"date":152,"type":35},{"date":179,"type":35},"2024-11-01",{"date":181,"type":21},"2025-12-01",{"name":41,"class":42},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":43},"100469372","effects-of-thyroidectomy-on-obstructive-sleep-apnea-in-patients-suffering-from-goiters-100469372","NCT05391945","Effects of Thyroidectomy on Obstructive Sleep Apnea in Patients Suffering From Goiters","Inclusion Criteria:\n\n°patients planned for thyroidectomy for goiter\n\nExclusion Criteria:\n\n* previous cervical surgery\u002Fradiotherapy\n* language barrier\n* chest disease known to narrow upper airways","90 Years",{"count":20,"type":21},"Literature regarding effects of goiter on the occurrence of obstructive sleep apnea (OSA) remains scarce. Reports have described cases of OSA in patients suffering from goiters, resolved after thyroidectomy.\n\nIt has been recently shown that goiters of a total volume exceeding 25 mL leads to \\>30% tracheal compression.\n\nThe aims of the present study is to assess 1) the prevalence of OSA in patients suffering from goiters and planned for thyroidectomy 2) the role of thyroidectomy in OSA resolution in patients suffering from pre-operative OSA 3) the identification of predictors for persisting OSA.",[193],"Goiter","2024-02-12",{"date":196,"type":35},"2024-02-13",{"date":198,"type":35},"2022-09-01",{"date":200,"type":21},"2026-12-01",{"name":41,"class":42},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":209,"targetDuration":211,"studyType":23,"phases":4,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},"100463519","changes-in-body-fat-and-morphologic-characteristics-associated-with-osa-resolution-after-bariatric-surgery-100463519","NCT05315752","Changes in Body Fat and Morphologic Characteristics Associated With OSA Resolution After Bariatric Surgery","Changes in Body Fat and Morphologic Characteristics Associated With Obstructive Sleep Apnea (OSA) Resolution After Bariatric Surgery","Inclusion Criteria:\n\nAny informed person who is\n\n* eligible for bariatric surgery: with severe obesity (BMI≥35-40) or morbid obesity (BMI≥40), with co-morbidities, who have not lost enough weight with prior lifestyle adaptations (balanced diet, physical activity) AND\n* with diagnosed obstructive sleep apnoea (OSA) (AHI \\> 15\u002Fhr on polysomnography) AND\n* requiring treatment with Continuous Positive Air Pressure (CPAP)\n\nExclusion Criteria:\n\n* Cognitive impairment - language barrier",{"count":210,"type":21},60,"12 Months","Prospective study with inclusion of bariatric surgery candidates with diagnosed Obstructive Sleep Apnea and requiring treatment with Continuous Positive Air Pressure, aiming to evaluate at 2-6-12 months after bariatric surgery whether the relationship between biometric changes (reduction in neck circumference, height, waist\u002Fhip ratio, and fat and lean mass) and the resolution of OSA is better than the relationship between these biometric changes and BMI reduction.",[214,215],"Obesity","Obstructive Sleep Apnea","2024-02-11",{"date":196,"type":35},{"date":219,"type":35},"2022-04-22",{"date":221,"type":21},"2026-12-31",{"name":41,"class":42},2,""]